Stock comparison
Halozyme Therapeutics
Galapagos N.V. Sponsored ADR
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
LKFT
Galapagos N.V. Sponsored ADR
Market cap
$1.81B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | LKFT | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 46D | HALO |
| Benjamin Graham | 83A | 45D | HALO |
| Philip Fisher | 65B | 53C | HALO |
| Peter Lynch | 53D | 60C | LKFT |
| Joel Greenblatt | 40D | 42D | LKFT |
| Charlie Munger | 80C | 46D | HALO |
| Terry Smith | 84A | 46D | HALO |
Side-by-side metrics
| Metric | HALO | LKFT |
|---|---|---|
| Market cap | $8.1B | $1.81B |
| P/E (TTM) | 24.0x | 3.1x |
| EV/EBIT | 10.2x | 2.9x |
| ROIC (TTM) | 23.65% | 18.22% |
| Gross margin | 81.24% | 98.01% |
| Net margin | 23.13% | 46.83% |
| Revenue CAGR 5y | 33.23% | - |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Market cap$8.1Bvs $1.81B+78%
- ROIC (TTM)23.65%vs 18.22%+23%
LKFT leads on
- Debt / Equity0.0xvs 1.0x+100%
- P/E (TTM)3.1xvs 24.0x+87%
- EV/EBIT2.9xvs 10.2x+71%
- Net margin46.83%vs 23.13%+51%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.